Pioneering biomarker technologies for Cancer therapies

Our biomarkers are used to identify the right patient, the right drug and the right dose.

Biomarker tests


Using our biomarker tests provides more effective treatment for patients and economic savings for the healthcare system. Our colorectal cancer tests are validated using thousands of patient samples and are set to transform the current treatment pathway.

Biomarker platforms


Our companion diagnostic biomarker platforms are used to discover biomarkers which improve both the benefit and risk profiles of pipeline drugs.


A functional genome-wide screen to discover companion diagnostic biomarkers that predict efficacy.


A genome-wide screen using the principles of toxgnostics to discover biomarkers that predict drug specific side-effects.

We are looking to partner with leading drug development companies for companion diagnostic development.

Contact us

We have reached a crossroads in cancer treatment, where we can apply innovative tests on the patient’s blood and tumour tissue to select which patients need chemotherapy, what drugs will be most effective and what is a safe dose, reducing the risk of side effects. Our portfolio of biomarker tests allows us to make a step change in the treatment of early stage colorectal cancer, a disease affecting 1.2 million new patients every year, presenting a major global burden of morbidity and mortality.”

Prof. David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci.

March 14, 2017

Chemotherapy side effect predicting Oxford biotech firm secures CE marking

Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy Oxford, UK, 14th March 2017 – FOR IMMEDIATE RELEASE Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow personalised medicine for cancer patients, has today announced the CE marking of ColoTox, its first in a series of in vitro diagnostic tests aimed at... more

November 9, 2016

Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity enters clinical studies

First patient enrolled in clinical utility study Oxford, UK, 9th November 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the first colorectal cancer patient was enrolled in the PRECISE trial featuring the ColoTox Assay. The PRECISE trial; ‘Predicting,... more

June 10, 2016

Oxford Cancer Biomarkers appoints Kathryn Kuhne as its Commercial and Marketing Director

Oxford, UK, 10 June 2016 Oxford Cancer Biomarkers has appointed Kathryn Kuhne as Commercial and Marketing Director, a key growth milestone for the company which aims to benefit cancer patients through developing molecular diagnostic tests that allow improved treatment decisions. Oxford Cancer Biomarkers uses its molecular insights into disease and pathological processes to develop innovative... more

Partnering with Pharmaceutical companies

We partner with leading pharmaceutical companies to develop cost effective companion biomarkers for pipeline drugs using our patented technology.

Learn more